ArticleFrontiers in psychology2026
High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson's disease.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment (CI) is a prevalent and debilitating non-motor symptom in Parkinson's disease (PD), yet reliable early diagnostic biomarkers are lacking. This study aimed to identify serum biomarkers associated with PD-CI and investigate the synergistic contributions of lipid metabolism and inflammatory signaling. Methods: In this retrospective, cross-sectional study, six candidate proteins (INPP5D, FLNA, ICAM-1, PCSK9, JAK1, and LCAT) were selected based on our previously published discovery-phase serum proteomics analysis and were quantified via ELISA in an independent cohort of 75 PD patients and 35 age-matched healthy controls (HCs). All participants underwent comprehensive cognitive assessments (MoCA, MMSE, CDR). Multivariate regression, receiver operating characteristic (ROC) analysis, and bioinformatics tools were employed to evaluate diagnostic potential and pathway associations. Results: PD patients showed significantly lower MoCA and MMSE scores than HC, accompanied by elevated serum ICAM-1, PCSK9, and JAK1, and decreased INPP5D and FLNA. Notably, as MoCA scores declined, serum ICAM-1, PCSK9, JAK1, and LCAT levels gradually increased, while INPP5D and FLNA decreased. ROC analysis indicated that these biomarkers, particularly PCSK9 and LCAT, effectively distinguished PD-NC from PD-CI. Bioinformatics analyses highlighted focal adhesion and JAK-STAT signaling as key pathways, with ICAM1 and ITGB2 as central nodes in the protein-protein interaction network. Conclusion: All six serum biomarkers showed potential in distinguishing PD-NC from PD-CI, with PCSK9 and LCAT being the most effective. The findings propose a pathogenic cascade integrating neuroinflammation, lipid metabolism, and cell adhesion dysfunction, offering new mechanistic insights and potential avenues for early diagnosis and therapeutic intervention in PD-CI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.